Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic NK cells + SLOG
- Development stage
- Unknown
- Lead developer
- Magicell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Allogeneic NK cells + SLOG** is a combination cell therapy consisting of allogeneic natural killer (NK) cells and SLOG (a proprietary formulation, details of which are not explicitly described in available resources, but used in combination for advanced solid tumor or lymphoma therapy)[5]. Allogeneic NK cells are immune effector cells derived from healthy donors, expanded and prepared for ready administration. These cells are capable of antigen-independent cytolytic activity against tumor cells, through mechanisms including recognition and destruction of abnormal cells, antibody-dependent cell-mediated cytotoxicity (ADCC), and cytokine release[1][2][3][4][6]. SLOG is administered in combination with allogeneic NK cells, and clinical trials suggest this combination therapy may potentiate antitumor effects. The mechanisms of action rely on the innate cytotoxic response of NK cells and enhancement strategies to increase their antineoplastic activity[1][5][6].
- Other names
- Magicell-NK + SLOG
Beyond the preview
Go deeper on allogeneic NK cells + SLOG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic NK cells + SLOG.